Intrafractional fiducial marker position variations in stereotactic liver radiotherapy during voluntary deep inspiration breath-hold.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
01 Dec 2020
Historique:
pubmed: 12 9 2020
medline: 15 12 2020
entrez: 11 9 2020
Statut: ppublish

Résumé

To evaluate intrafractional fiducial marker position variations during stereotactic body radiotherapy (SBRT) in patients treated for liver metastases in visually guided, voluntary deep inspiration breath-hold (DIBH). 10 patients with implanted fiducial markers were studied. Respiratory coaching with visual guidance was used to ensure comfortable voluntary breath-holds for SBRT imaging and delivery. Three DIBH CTs were acquired for treatment planning. Pre- and post-treatment CBCTs were acquired for each of the three treatment fractions. Per-fraction marker position was evaluated on planar 2D kV images acquired during treatment fractions for 4 of the 10 patients. The median difference in marker position was 0.3 cm (range, 0.0-0.9 cm) between the three DIBH CTs and 0.3 cm (range, 0.1 to 1.4 cm) between pre- and post-treatment CBCTs. The maximum intrafractional variation in marker position in craniocaudal (CC) direction on planar kV images was 0.7 to 1.3 cm and up to 1.0 cm during a single DIBH. Difference in marker position of up to 1.0 cm was observed during a single DIBH despite use of narrow external gating window and visual feedback. Stability examination on pre-treatment DIBH CTs was not sufficient to guarantee per-fraction stability. Evaluation of differences in marker position on pre- and post-treatment CBCT did not always reveal the full magnitude of the intrafractional variation. To increase treatment accuracy, it is necessary to apply real-time monitoring of the tumour or a reliable internal surrogate when delivering liver SBRT in voluntary DIBH.

Identifiants

pubmed: 32915653
doi: 10.1259/bjr.20200859
pmc: PMC7716004
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20200859

Références

Med Phys. 2007 Sep;34(9):3620-9
pubmed: 17926966
Radiother Oncol. 2017 Apr;123(1):78-84
pubmed: 28245908
Phys Med Biol. 2018 Jul 16;63(14):145010
pubmed: 29923837
Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):132-140
pubmed: 28490984
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1201-8
pubmed: 19386435
Phys Med Biol. 2011 Sep 7;56(17):5445-68
pubmed: 21813963
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):302-8
pubmed: 19628342
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):366-375
pubmed: 29559289
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):190-7
pubmed: 23414764
Radiother Oncol. 2016 Oct;121(1):75-78
pubmed: 27555229
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1247-52
pubmed: 15990028
Adv Radiat Oncol. 2018 Aug 23;4(1):142-149
pubmed: 30706022
Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1410-21
pubmed: 11728702
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1573-83
pubmed: 20399034
Br J Radiol. 2016 Dec;89(1068):20160544
pubmed: 27706950
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):751-9
pubmed: 16458774
J Appl Clin Med Phys. 2018 Jan;19(1):39-45
pubmed: 29152835
Radiat Oncol. 2019 Jun 3;14(1):93
pubmed: 31159840
Radiother Oncol. 2018 Feb;126(2):339-346
pubmed: 28992962
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):297-304
pubmed: 18406894
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):630-8
pubmed: 17236980
Strahlenther Onkol. 2020 Aug;196(8):691-698
pubmed: 32002567
Med Phys. 2012 Oct;39(10):6431-42
pubmed: 23039678
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):907-15
pubmed: 18514783
Radiother Oncol. 2018 Dec;129(3):441-448
pubmed: 30033386
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):478-92
pubmed: 26867877
Acta Oncol. 2017 Jun;56(6):860-866
pubmed: 28464747
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):610-9
pubmed: 16966004
Phys Med. 2019 Sep;65:46-52
pubmed: 31430586

Auteurs

Line Bjerregaard Stick (LB)

Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Niels Bohr Institute, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.

Ivan Richter Vogelius (IR)

Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Signe Risum (S)

Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Mirjana Josipovic (M)

Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH